Answers are grounded in this paper and cite their sources.
Background and Objective Urinary tract infection (UTI) is prevalent among individuals with neurodegenerative diseases, including multiple sclerosis (MS), dementia, and Parkinsonian disorders. Beyond its contribution to morbidity and healthcare utilization, UTI may adversely influence neurological disease trajectories through immune and metabolic mechanisms. Despite the prevalence and impact of UTI in individuals with neurodegenerative conditions, the evidence supporting medical strategies for UTI prevention in these populations has not been systematically evaluated. We sought to systematically review the evidence for medical prophylaxis against recurrent UTI in adults with neurodegenerative diseases and to identify gaps in knowledge informing future research priorities. Methods A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025632760). PubMed (MEDLINE) and the Cochrane Library were searched through December 2024. Studies that evaluated medical strategies for UTI prevention in adults with neurodegenerative conditions and reported clinical UTI outcomes were included. Risk of bias was assessed. Given the significant study heterogeneity identified, a narrative synthesis was performed. Results Seven studies, encompassing 630 adults (480 of whom had MS) with neurogenic lower urinary tract dysfunction, met inclusion criteria. All studies involved individuals with MS, and no eligible studies addressed UTI prevention in dementia or Parkinsonian disorders or amyotrophic lateral sclerosis. Interventions included bladder evacuation strategies, intradetrusor botulinum toxin A injections, D-mannose supplementation, oral immunotherapy (OM-89), cranberry supplementation, and antimicrobial prophylaxis. Botulinum toxin A, D-mannose, and antimicrobial prophylaxis demonstrated potential reductions in UTI frequency in selected MS populations, though evidence was limited by small sample sizes, nonrandomized designs, and heterogeneous outcome definitions. Cranberry supplementation and oral immunotherapy showed no efficacy in randomized controlled trials, though small sample size may have contributed. Antimicrobial resistance emerged as the principal safety concern with long-term antibiotic prophylaxis. No study assessed neurological disease progression as an outcome. Conclusions UTI represents a potentially modifiable but underexplored contributor to neurodegenerative disease progression. Yet, evidence supporting medical UTI prophylaxis in neurodegenerative diseases is sparse and confined to MS, with no trials identified in dementia, Parkinsonian disorders, or amyotrophic lateral sclerosis. High-quality randomized trials are needed to determine whether UTI prevention can favorably modify neurological outcomes.
No takes yet. Share an insight, caveat, or question.
Werneburg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: